Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial. by Landovitz, Raphael J et al.
UCLA
UCLA Previously Published Works
Title
Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk 
HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial.
Permalink
https://escholarship.org/uc/item/8br3w4jf
Journal
PLoS medicine, 15(11)
ISSN
1549-1277
Authors
Landovitz, Raphael J
Li, Sue
Grinsztejn, Beatriz
et al.
Publication Date
2018-11-08
DOI
10.1371/journal.pmed.1002690
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
RESEARCH ARTICLE
Safety, tolerability, and pharmacokinetics of
long-acting injectable cabotegravir in low-risk
HIV-uninfected individuals: HPTN 077, a phase
2a randomized controlled trial
Raphael J. LandovitzID1*, Sue Li2, Beatriz GrinsztejnID3, Halima Dawood4, Albert Y. LiuID5,
Manya Magnus6, Mina C. HosseinipourID7, Ravindre Panchia8, Leslie Cottle2,
Gordon Chau2, Paul Richardson9, Mark A. MarzinkeID9, Craig W. HendrixID9, Susan
H. EshlemanID9, Yinfeng Zhang9, Elizabeth TolleyID10, Jeremy Sugarman9,11,
Ryan Kofron1, Adeola Adeyeye12, David Burns12, Alex R. Rinehart13, David Margolis13,
William R. Spreen13, Myron S. Cohen14, Marybeth McCauley10, Joseph J. EronID14
1 UCLA Center for Clinical AIDS Research and Education, Los Angeles, California, United States of America,
2 Statistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle,
Washington, United States of America, 3 Evandro Chagas National Institute of Infectious Diseases, Oswaldo
Cruz Foundation, Rio de Janeiro, Brazil, 4 Centre for the AIDS Programme of Research in South Africa,
University of KwaZulu Natal, Durban, South Africa, 5 Bridge HIV, Population Health Division, San Francisco
Department of Health, San Francisco, California, United States of America, 6 Department of Epidemiology and
Biostatistics, Milken Institute School of Public Health, George Washington University, Washington, District of
Columbia, United States of America, 7 UNC Project–Malawi, Lilongwe, Malawi, 8 Perinatal HIV Research Unit,
Chris Hani Baragwanath Hospital, Soweto, South Africa, 9 School of Medicine, Johns Hopkins University,
Baltimore, Maryland, United States of America, 10 FHI360, Durham, North Carolina, United States of America,
11 Berman Institute of Bioethics, Johns Hopkins University, Baltimore, Maryland, United States of America,
12 Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville,
Maryland, United States of America, 13 ViiV Healthcare, Durham, North Carolina, United States of America,
14 University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America
* rlandovitz@mednet.ucla.edu
Abstract
Background
Cabotegravir (CAB) is a novel strand-transfer integrase inhibitor being developed for HIV
treatment and prevention. CAB is formulated both as an immediate-release oral tablet for
daily administration and as a long-acting injectable suspension (long-acting CAB [CAB LA])
for intramuscular (IM) administration, which delivers prolonged plasma exposure to the drug
after IM injection. HIV Prevention Trials Network study 077 (HPTN 077) evaluated the
safety, tolerability, and pharmacokinetics of CAB LA in HIV-uninfected males and females
at 8 sites in Brazil, Malawi, South Africa, and the United States.
Methods and findings
HPTN 077 was a double-blind, placebo-controlled phase 2a trial. Healthy individuals age
18–65 years at low HIV risk were randomized (3:1) to receive CAB or placebo (PBO). In the
initial oral phase, participants received 1 daily oral tablet (CAB or PBO) for 4 weeks. Those
without safety concerns in the oral phase continued and received injections in the injection
phase (Cohort 1: 3 injections of CAB LA 800 mg or 0.9% saline as PBO IM every 12 weeks
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for 3 injection cycles; Cohort 2: CAB LA 600 mg or PBO IM for 5 injection cycles; the first 2
injections in Cohort 2 were separated by 4 weeks, the rest by 8 weeks). The primary analysis
included weeks 5 to 41 of study participation, encompassing the injection phase. The cohorts
were enrolled sequentially. Primary outcomes were safety and tolerability. Secondary out-
comes included pharmacokinetics and events occurring during the oral and injection phases.
Between February 9, 2015, and May 27, 2016, the study screened 443 individuals and
enrolled 110 participants in Cohort 1 and 89 eligible participants in Cohort 2. Participant popu-
lation characteristics were as follows: 66% female at birth; median age 31 years; 27% non-
Hispanic white, 41% non-Hispanic black, 24% Hispanic/Latino, 3% Asian, and 6% mixed/
other; and 6 transgender men and 1 transgender woman. Twenty-two (11%) participants dis-
continued the oral study product; 6 of these were for clinical or laboratory adverse events
(AEs). Of those who received at least 1 CAB LA injection, 80% of Cohort 1 and 92% of Cohort
2 participants completed all injections; injection course completion rates were not different
from those in the PBO arm. Injection site reactions (ISRs) were common (92% of Cohort 1
and 88% of Cohort 2 participants who received CAB LA reported any ISR). ISRs were mostly
Grade 1 (mild) to Grade 2 (moderate), and 1 ISR event (Cohort 1) led to product discontinua-
tion. Grade 2 or higher ISRs were the only AEs reported more commonly among CAB LA
recipients than PBO recipients. Two Grade 3 (severe) ISRs occurred in CAB recipients, 1 in
each cohort, but did not lead to product discontinuation in either case. Seven incident sexu-
ally transmitted infections were diagnosed in 6 participants. One HIV infection occurred in a
participant 48 weeks after last injection of CAB LA: CAB was not detectable in plasma both at
the time of first reactive HIV test and at the study visit 12 weeks prior to the first reactive test.
Participants in Cohort 2 (unlike Cohort 1) consistently met prespecified pharmacokinetic tar-
gets of at least 95% of participants maintaining CAB trough concentrations above PA-IC90,
and 80% maintaining trough concentrations above 4× PA-IC90. Study limitations include a
modest sample size, a short course of injections, and a low-risk study population.
Conclusions
In this study, CAB LA was well tolerated at the doses and dosing intervals used. ISRs were
common, but infrequently led to product discontinuation. CAB LA 600 mg every 8 weeks
met pharmacokinetic targets for both male and female study participants. The safety and
pharmacokinetic results observed support the further development of CAB LA, and efficacy
studies of CAB LA for HIV treatment and prevention are in progress.
Trial registration
ClinicalTrials.gov Registry: ClinicalTrials.gov Trial number: NCT02178800.
Author summary
Why was this study done?
• Daily oral pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate/emtrici-
tabine is highly effective in preventing HIV infection when taken as prescribed, but
adherence challenges have compromised full effectiveness in some populations.
Safety, tolerability and pharmacokinetics of CAB LA in low-risk HIV-uninfected individuals
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• Cabotegravir (CAB) is a novel strand-transfer integrase inhibitor in development as a
long-acting injectable preparation for HIV treatment and HIV prevention.
• HIV Prevention Trials Network study 077 (HPTN 077) aimed to establish the safety, tol-
erability, and pharmacokinetics of 2 dose/interval regimens of long-acting CAB in HIV-
uninfected, low-risk individuals globally.
What did the researchers do and find?
• Participants were randomized to active CAB or placebo. All participants received a 4-
week daily oral lead-in of CAB or placebo, followed by a series of injections of CAB or
placebo. Participants received either 800 mg as a split 2-ml injection every 12 weeks, or
600 mg as a single 3-ml injection every 8 weeks, after receiving 2 injections 4 weeks
apart.
• We observed frequent injection site reactions (mostly injection site pain), and they were
more common with CAB than placebo, but only led to discontinuation of injections in
rare cases. No other safety concerns were noted.
• Pharmacokinetics, using target values from nonhuman primate simian/human immu-
nodeficiency virus challenge prevention studies, support the 600 mg every 8 weeks dose,
meeting prespecified targets.
What do these findings mean?
• We found that CAB was generally well tolerated in HIV-uninfected males and females
in diverse geographic locations.
• Injection site reactions, although frequent, did not deter continued dosing, albeit with
short courses.
• Studies are ongoing to evaluate efficacy in at-risk populations and to further evaluate
the safety of the 600 mg every 8 weeks dose.
Introduction
Oral tenofovir disoproxil fumarate (TDF)–based pre-exposure prophylaxis (PrEP) is highly
effective for HIV prevention when taken as prescribed [1–5]. However, achieving and main-
taining adherence rates sufficient for high-level protection against HIV is challenging for some
individuals and populations [6–8]. Impediments to adherence with daily tablets may be as sim-
ple as forgetfulness but could involve more complicated reasons such as concerns about safety,
stigma related to use, and potential harms if PrEP use is disclosed to sexual partners. Lessons
learned from contraceptive technology suggest that an increased variety of product types for
PrEP will increase the probability that at least 1 product will fit a given individual’s needs at a
particular time [9]. For these reasons, there is interest in development and evaluation of HIV
prevention agents that do not require daily adherence.
Safety, tolerability and pharmacokinetics of CAB LA in low-risk HIV-uninfected individuals
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Cabotegravir (CAB) is an investigational strand-transfer integrase inhibitor with potent
activity against HIV in vitro and in vivo [10,11]. CAB is formulated both as an oral tablet for
daily administration and as a long-acting injectable suspension (long-acting CAB [CAB LA])
[12]. CAB LA is currently under development for HIV treatment in combination with long-
acting injectable rilpivirine (NCT02951052 and NCT02938520) [13,14] and as a stand-alone
antiviral agent for HIV prevention (NCT02720094 and NCT03164564). Nonhuman primate
(NHP) models have demonstrated that CAB LA can protect against rectal, vaginal, parenteral,
and penile simian immunodeficiency virus and simian/human immunodeficiency virus
(SHIV) challenges [15–20]. In those studies, high levels of protection were seen against
repeated exposures when CAB plasma concentrations were above 4 times the protein-adjusted
IC90 (PA-IC90) (0.664 μg/ml), and were generally maintained at drug concentrations above the
PA-IC90 (0.166 μg/ml).
In humans, the safety and pharmacokinetics of CAB LA were evaluated in a phase 2a trial,
the ECLAIR trial, that enrolled HIV-uninfected low-risk men in the US [21]. This trial investi-
gated CAB LA at a dose of 800 mg IM every 12 weeks. The ECLAIR study demonstrated that
CAB LA was safe and well tolerated, but prespecified pharmacokinetic targets established from
the NHP models for preventive efficacy were not consistently met [21]. In vitro data and data
from NHP studies were used to set pharmacokinetic targets prior to study inception. The tar-
get median trough concentration was set at 1.35 μg/ml, which, if achieved, was predicted to
attain trough concentrations of greater than or equal to 4× the PA-IC90 (0.664 μg/ml) in 80%
of participants and greater than or equal to the PA-IC90 (0.166 μg/ml) in 95% of participants.
In NHP models, no transmissions were observed with rectal or vaginal challenge when the
concentration of CAB remained above 4× the PA-IC90, and most animals were protected
when concentrations remained above the PA-IC90. No major integrase resistance mutations
were found in SHIV isolates from NHP models of rectal and vaginal challenges where infec-
tions occurred during the pharmacokinetic tail [18,20].
Subsequent to the ECLAIR results, modeling based on datasets from both HIV-infected
and HIV-uninfected individuals in ongoing studies suggested that a dose of 600 mg IM every 8
weeks, following an initial 4-week interval between first and second injections, is more likely
to meet these pharmacokinetic targets. Accordingly, HIV Prevention Trials Network study
077 (HPTN 077) was undertaken to evaluate the safety, tolerability, and pharmacokinetics of
CAB LA at 2 doses and intervals (800 mg every 12 weeks and 600 mg every 8 weeks) in HIV-
negative, low-risk males and females in the US and resource-constrained countries as a requi-
site step in the development of CAB LA for PrEP for HIV.
Methods
Study design and participants
HPTN 077 is a randomized, double-blind placebo-controlled phase 2a trial conducted at 8 sites
in Brazil, Malawi, South Africa, and the US. Participants were 18–65 years old, HIV uninfected
at screening (determined using a US Food and Drug Administration [FDA]–cleared HIV
rapid test, instrumented fourth generation antigen/antibody testing, and an HIV RNA test
within 2 weeks of study entry), and at low risk for HIV infection (low infection risk was defined
as no condomless anal or vaginal intercourse with HIV-infected or serostatus-unknown part-
ners; no stimulant, inhaled nitrate, or injection drug use; no diagnosis of a sexually transmitted
infection [STI]; and having fewer than 5 sexual partners—all in the past 12 months by self-
report). Participants were generally in good health, with hemoglobin> 11 g/dl, absolute neutro-
phil count> 750 cells/mm3, platelets> 100,000/mm3, creatinine clearance� 70 ml/min, nor-
mal aspartate aminotransferase and alanine aminotransferase values, and negative tests for
Safety, tolerability and pharmacokinetics of CAB LA in low-risk HIV-uninfected individuals
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hepatitis B and C virus infection. Females who were of reproductive potential were required to
use an effective contraception method. Individuals were not eligible for enrollment if they had
significant cardiovascular disease; had used post-exposure prophylaxis or PrEP in the 90 days
prior to study entry; had known liver disease, coagulopathy, or seizures (added to exclusionary
conditions mid-study); were pregnant or breastfeeding; or had a score of�8 on the Alcohol
Use Disorders Identification Test (AUDIT) [22]. The study was carried out according to the
study protocol (S1 Text) except where specifically noted, and is reported according to CON-
SORT (S1 CONSORT Checklist). The institutional review board or ethics committee at each
participating site approved the protocol, and all participants provided written informed con-
sent. The trial was registered as NCT02178800 at ClinicalTrials.gov.
Randomization and masking
Participants were randomly assigned 3:1 by a computer-generated algorithm stratified by sex
at birth and region (US or non-US) to CAB or placebo (PBO). CAB LA and 0.9% saline PBO
injections were further masked with semi-opaque syringe overlays. Site pharmacists were not
blinded to treatment assignments in order to provide appropriate study product; other study
personnel and study participants remained blinded to treatment assignments from study entry
until all participants completed the week 41 study visit and all data for the primary endpoint
(i.e., the week 41 time point) had been collected. One laboratory investigator was unblinded
for the purpose of selecting samples for CAB concentration testing; the unblinding informa-
tion was not shared with any other study staff.
Procedures
Participants were enrolled in 2 sequential cohorts with different dosing regimens. In the initial
oral phase, randomized participants in both cohorts received 30 mg oral CAB or a matching
oral PBO tablet daily for 4 weeks. HIV infection, safety, and tolerability were assessed after 2
and 4 weeks on study products. Participants proceeded to the injection phase of the study if
they had adequate safety and tolerability measures and if they had at least 75% adherence to
the oral study product (assessed by pill count) at the week 4 visit. The safety requirements for
progression to the injection phase of the trial were stringent at the suggestion of the FDA (S1
Text).
Cohort 1 participants received 800 mg CAB LA (administered as two 400-mg [2 ml] IM
injections) or 0.9% saline PBO. Injections of CAB LA and PBO were administered in the glu-
teal muscle, at weeks 5, 17, and 29 (every 12 weeks); this was the same dosing regimen used in
the ECLAIR trial in men from the US. The primary endpoint was reached at week 41 (12
weeks after the final injection). HIV testing, laboratory and clinical safety assessments, and
CAB plasma concentration measurements occurred at injection visits and at weeks 6, 9, 13, 18,
23, 30, 35, and 41 (Fig 1A).
Cohort 2 was added by protocol amendment following the results from the ECLAIR study
in order to provide data on an alternative dosing scheme predicted to more consistently
achieve pharmacokinetic targets. In Cohort 2, participants received 600 mg CAB LA or 0.9%
saline PBO, administered as a single (3 ml) IM injection in the gluteal muscle. Injections were
administered at weeks 5, 9, 17, 25, and 33 (every 8 weeks after a 4-week interval between the
first and second injections). As in Cohort 1, the primary endpoint was reached at week 41 (8
weeks after the final injection). HIV testing, laboratory and clinical safety assessments, and
CAB plasma concentration measurements occurred at injection visits and at weeks 6, 10, 13,
18, 21, 26, 29, 34, 37, and 41 (Fig 1B).
Safety, tolerability and pharmacokinetics of CAB LA in low-risk HIV-uninfected individuals
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In both cohorts, PBO-treated participants were discontinued from long-term follow-up at
the time of unblinding. Participants in both cohorts who received active CAB continued on
quarterly follow-up for 52–76 weeks after their final injection. Participants who enrolled near
the start of the study had only 52 weeks of follow-up, as designated by the protocol; follow-up
was extended to 76 weeks for participants enrolled later in the study, when results from long-
term follow-up in the ECLAIR study became available.
Outcome assessments
The primary analysis included weeks 5 to 41 of study participation, encompassing the injection
phase. The cohorts were enrolled sequentially. Primary outcomes were safety and tolerability.
Secondary outcomes included pharmacokinetics and events occurring during the oral and
injection phases. Additional clinical events of interest (HIV seroconversion and pregnancy in
the tail-phase of the study) are also reported. All injection and safety visits included clinical
and laboratory assessments for adverse events (AEs), HIV testing (using an FDA-approved
HIV rapid test and instrumented antigen/antibody testing at all visits), injection site reaction
(ISR) evaluation, vital signs, clinical examination, and review of concomitant medications. AEs
were graded according to the Division of AIDS Table for Grading the Severity of Adult and
Pediatric Adverse Events, Version 2.0 [23]. The satisfaction with study products and preferences
were assessed at enrollment and 1 week after each injection; sexual risk behavior was assessed at
enrollment, at injection visits, and at 12-week intervals during follow-up. Testing for STIs
Fig 1. Study design. (A) Cohort 1 (CAB LA 800 mg or 0.9% saline PBO IM every 12 weeks). (B) Cohort 2 (CAB LA 600 mg or 0.9% saline PBO IM every 8 weeks after
an initial 4-week interval). CAB, cabotegravir; CAB LA, long-acting cabotegravir; IM, intramuscular; PBO, placebo; PO, by mouth; QD, once daily.
https://doi.org/10.1371/journal.pmed.1002690.g001
Safety, tolerability and pharmacokinetics of CAB LA in low-risk HIV-uninfected individuals
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included urine and rectal Neisseria gonorrhoeae and Chlamydia trachomatis nucleic acid ampli-
fication testing and serologic syphilis testing at screening, and at approximately 6-month inter-
vals throughout the study to monitor for changes in risk for HIV acquisition. For females of
reproductive potential, pregnancy testing was performed in both cohorts at screening, enroll-
ment, weeks 2 and 4, injection visits prior to each injection, the week 41 primary endpoint visit,
and each quarterly follow-up visit. Electrocardiograms were performed at screening, enroll-
ment, and weeks 4, 6, 9, 23, and 35 in Cohort 1 and weeks 4, 6, 13, 21, 29, and 37 in Cohort 2.
Plasma CAB concentrations were measured using a validated liquid chromatographic–
mass spectrometric (LC-MS/MS) assay with a lower limit of quantification (LLOQ) of
0.025 μg/ml. On visits at which injections were administered, CAB concentrations were mea-
sured using samples collected prior to injection.
For the participant who acquired HIV infection, HIV drug resistance testing was retrospec-
tively performed using the ViroSeq HIV-1 Genotyping System, version 2.0, and the ViroSeq
HIV-1 Integrase Genotyping Kit (Abbott Molecular, Des Plaines, IL). HIV drug resistance
testing was also performed using a research assay based on next generation sequencing (NGS)
(see S2 Text).
Primary study outcomes were (1) safety, as determined by the proportion of participants
experiencing any Grade 2 or higher clinical AE or any laboratory abnormality occurring from
the initial injection at week 5 to the primary endpoint visit at week 41 among participants who
received at least 1 injection, and (2) tolerability, as determined by the proportion of partici-
pants who discontinued injections before receiving the full course of injections for reasons of
intolerability of injection (including but not limited to ISRs, injection burden or frequency, or
any clinical or laboratory AE).
Statistical analysis
The primary analysis is limited to data collected through the primary endpoint (week 41) and
included all participants who met eligibility criteria and were exposed to any study product.
Comparisons of baseline demographics between CAB and PBO treatment arms were done
using the chi-squared test for categorical variables and Wilcoxon rank sum test for continuous
variables. For the primary endpoint, a modified intention-to-treat analysis was conducted that
included participants who received at least 1 injection. Fisher’s exact test was used to compare
the proportion of participants in the CAB versus PBO treatment arm who experienced any
Grade 2 or higher clinical AE or laboratory abnormality between the first injection at week 5
and the primary endpoint visit at week 41. Participants in the CAB treatment arm who
received at least 1 injection were included in the analysis of plasma CAB concentrations. The
means and the 90% prediction intervals at visits were estimated using linear mixed models.
Plasma CAB concentrations were log-transformed before they were fitted to a linear mixed
model. The geometric means of CAB concentrations were compared between participants
who were males and females at birth using the Wald test in the linear mixed model.
Pharmacokinetic parameters were calculated for each participant who received active CAB.
Non-compartmental analysis was used to estimate the area under the plasma concentration–
time curve over the dosing interval (AUC0–τ), maximum plasma concentration (Cmax), and
trough concentration at the end of the dosing interval (Cτ). Concentrations below the LLOQ
(0.025 μg/ml) were imputed as LLOQ/2 prior to the estimations. Plasma CAB concentrations
were summarized from samples collected within defined post-injection sampling windows by
sex at birth and cohort. The geometric means of pharmacokinetic parameters were estimated
using the linear mixed model and compared between males and females and by body mass
index (BMI) continuously and by BMI group (�median versus <median,�25 versus<25 kg/
Safety, tolerability and pharmacokinetics of CAB LA in low-risk HIV-uninfected individuals
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m2, and�30 versus<30 kg/m2) by the Wald test. Other than comparisons of pharmacokinetic
parameters, all comparisons between sexes were post hoc analyses. Tests with p-values� 0.05
were considered to be statistically significant.
Safety was evaluated for CAB LA overall (Cohort 1 and Cohort 2 combined) and for each
individual cohort. The ability of the study to detect serious adverse events (SAEs) was
expressed by the true event rate above which at least 1 SAE would likely be observed and the
true event rate below which no events would likely be observed. Specifically, for the CAB arm
overall (n = 134), there was a 90% chance of observing no events if the true rate was 0.1% or
less. Similarly, for the CAB arm in individual cohorts (n = 74 for Cohort 1; n = 60 for Cohort
2), there was a 90% chance of observing at least 1 event if the true rate of such an event was
3.1% or more for Cohort 1 and 3.8% or more for Cohort 2, and there was a 90% chance of
observing no events if the true rate was 0.1% or less for both cohorts. The study had over 80%
power to detect a 13%–26% difference in the proportion of participants experiencing a Grade
2 or higher clinical AE or laboratory abnormality between the CAB (n = 134) and PBO (n =
43) treatment arms if the proportion of participants with a Grade 2 or higher clinical AE or
laboratory abnormality in the PBO arm ranged from 0% to 50%.
Results
A total of 443 individuals were screened, and 200 participants were enrolled (Fig 2). The most
frequent reasons for screening failure were not meeting the protocol’s low-risk or clinical
inclusion criteria. One hundred ten participants were enrolled in Cohort 1 and were random-
ized 3:1 CAB to PBO (82 CAB and 28 PBO) from February 9, 2015, to September 16, 2015.
Cohort 2 enrolled an additional 89 eligible participants (69 CAB and 20 PBO) from December
18, 2015, to May 27, 2016. Overall, the median age was 31 years (interquartile range [IQR] 24,
40); 132 (66%) were female at birth, with most female participants enrolled in Malawi, South
Africa, and the US. The study population included 6 transgender men and 1 transgender
woman. For analysis purposes, participants were identified by sex at birth. Participants were
27% non-Hispanic white, 41% non-Hispanic black, 24% Hispanic/Latino, 3% Asian, and 6%
mixed/other. The demographics were similar between the 2 cohorts and were not significantly
different between Cohort 1 and Cohort 2 (Table 1).
Fig 2 shows participant disposition during the study. In Cohort 1, 90% of participants ran-
domized to the CAB arm completed the oral phase and received at least 1 injection; 72% com-
pleted all 3 injections. In Cohort 2, 87% of participants in the CAB arm completed the oral
phase; 80% completed the oral phase and received all 5 injections. Of those receiving at least 1
active CAB injection, 80% of Cohort 1 and 92% of Cohort 2 participants completed the full
course of injections. There were no statistically significant differences between the CAB and
PBO arms in the proportions of participants who entered the injection phase or completed all
injection visits. Although injection course completion rates were numerically higher for males
than for females in both cohorts (Fig 2; S1 Table), these differences were not statistically signif-
icant. Most germane to the phase 3 development program of CAB LA for HIV prevention,
95% of males and 90% of females in Cohort 2 who began the injection phase completed all 5
injections.
Forty-nine participants discontinued the injectable study product. The most common rea-
sons for the discontinuation of study product (CAB and PBO) were unwillingness or inability
to comply with study procedures (12 events), protocol-specified study-product-related clinical
AEs (10 events), and protocol-specified lab abnormalities (7 events). Rates of study product
discontinuation due to clinical or laboratory abnormalities were not different for males and
females; product discontinuation rates were also not different between participants in the CAB
Safety, tolerability and pharmacokinetics of CAB LA in low-risk HIV-uninfected individuals
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and PBO arms (Fig 3; S2 Table). One participant in the CAB arm of Cohort 1 discontinued
study product due to a Grade 2 ISR.
The 10 study product discontinuations (Fig 3; S2 Table) for clinical AEs among active CAB
recipients included 1 gastrointestinal event (constipation), 3 rash/urticaria events, 6 neurologic
events, including headaches (2), neuropathy (1), transient weakness (1), papilledema (1), and a
seizure event in a participant with a preexisting history of seizure disorder (1). Four SAEs
occurred in participants in CAB arms, including vertigo, transient weakness, laryngitis, and
acute kidney injury; the latter 2 events were assessed by study site investigators and determined
to be unrelated to study products. Two SAEs occurred in participants in the PBO arms, includ-
ing 1 episode of cholelithiasis and 1 spontaneous loss of pregnancy at 11 weeks of gestation.
Fig 2. Study consort diagram. �One participant excluded due to exclusionary condition at enrollment. AE, adverse event; CAB, cabotegravir; PBO, placebo; STI,
sexually transmitted infection.
https://doi.org/10.1371/journal.pmed.1002690.g002
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Overall, 122 (91%) participants in the CAB arm reported at least 1 Grade 2 or higher AE
during the injection phase, compared with 38 (88%) of participants in the PBO arm (p = 0.56;
Table 2). The most commonly reported Grade 2 or higher AEs were decreased creatinine
clearance by Cockcroft–Gault calculation, at similar rates in each arm (63 [47%] in the CAB
arm and 20 [46.5%] in the PBO arm, p = 1.0; Table 2). The only Grade 2 or higher clinical AEs
that were more common in the CAB arm compared to the PBO arm were ISRs (51 [38%] in
the CAB arm and 1 [2%] in the PBO arm, p< 0.001; Table 2). ISRs of any grade, mostly Grade
1 (mild) to Grade 2 (moderate), were reported in the CAB arm by 92% of participants in
Cohort 1 (Fig 4A) and 88% of participants in Cohort 2 (Fig 4B); ISRs of any grade were less fre-
quent in the PBO arm (24% in Cohort 1 and 39% in Cohort 2). For the CAB arm overall, ISR
events declined with subsequent injections; ISR event rates were similar for male and female
participants receiving CAB across both cohorts (91% versus 90%, p = 1.0) (S1 Fig). One Grade
3 (severe) ISR occurred in a CAB recipient in each cohort; neither resulted in discontinuation
of study products. No participant discontinued study products due to protocol-specified elec-
trocardiographic changes.
Two pregnancies occurred in participants in the PBO arm of the study. One resulted in a
miscarriage at 11 weeks, likely due to Zika virus infection, and 1 led to a full-term, healthy
infant without apparent congenital anomalies. A third female participant became pregnant
Table 1. Demographics by cohort and treatment arm.
Characteristic Cohort 1 Cohort 2 p-Value�
Overall CAB PBO Overall CAB PBO
Age, median (IQR) 33 (25, 42) 30 (24, 41) 35 (27, 42) 31 (24, 37) 30 (23, 36) 33 (25, 39) 0.211
BMI, median (IQR) 27 (24, 32) 27 (24, 33) 26 (24, 32) 26 (23, 33) 26 (22, 32) 28 (24, 34) 0.256
Weight, median (IQR) 76 (67, 91) 78 (68, 94) 75 (66, 87) 73 (61, 93) 72 (60, 86) 74 (62, 100) 0.165
Sex at birth, n (%)
Female 72 (65%) 54 (66%) 18 (64%) 60 (67%) 46 (67%) 14 (70%) 0.771
Male 38 (35%) 28 (34%) 10 (36%) 29 (33%) 23 (33%) 6 (30%)
Sex at birth and region, n (%)
Female
US 32 (44%) 24 (44%) 8 (44%) 25 (42%) 19 (41%) 6 (43%) 0.637
Brazil 11 (15%) 8 (15%) 3 (17%) 13 (22%) 8 (17%) 5 (36%)
Sub-Saharan Africa 29 (40%) 22 (41%) 7 (39%) 22 (37%) 19 (41%) 3 (21%)
Male
US 31 (82%) 23 (82%) 8 (80%) 18 (62%) 14 (61%) 4 (67%) 0.115
Brazil 5 (13%) 4 (14%) 1 (10%) 5 (17%) 4 (17%) 1 (17%)
Sub-Saharan Africa 2 (5%) 1 (4%) 1 (10%) 6 (21%) 5 (22%) 1 (17%)
Transgender, n (%)
Female 0 (0%) 0 (0%) 0 (0%) 1 (1.7%) 1 (2.2%) 0 (0%) 1.000
Male 3 (7.9%) 3 (10.7%) 0 (0%) 3 (10.3%) 1 (4.3%) 2 (33.3%)
Race/ethnicity, n (%)
Non-Hispanic white 36 (33%) 29 (35%) 7 (25%) 18 (20%) 13 (19%) 5 (25%) 0.162
Non-Hispanic black 42 (38%) 31 (38%) 11 (39%) 40 (45%) 33 (48%) 7 (35%)
Hispanic/Latino 24 (22%) 19 (23%) 5 (18%) 23 (26%) 17 (25%) 6 (30%)
Asian 1 (1%) 0 (0%) 1 (4%) 4 (4%) 3 (4%) 1 (5%)
Mixed/other 7 (6%) 3 (4%) 4 (14%) 4 (4%) 3 (4%) 1 (5%)
�p-Value for the comparison between Cohort 1 and Cohort 2 participant characteristics.
CAB, cabotegravir; PBO, placebo.
https://doi.org/10.1371/journal.pmed.1002690.t001
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during the tail-phase of the study (after the period of primary analysis covered in this paper), 8
months after her fifth and final injection of active CAB. Her pregnancy was complicated by
preeclampsia; however, she delivered a healthy, early-term (38 5/7 weeks) [24] child without
birth defects.
One participant acquired HIV during the study: a female participant at a site in sub-Saha-
ran Africa in Cohort 1, 48 weeks after the final injection of active CAB. The participant’s
plasma CAB concentration was below the LLOQ (0.025 μg/ml) at the visit at which HIV infec-
tion was first detected, and also at a visit 12 weeks prior, when the participant had non-reac-
tive/negative HIV tests with undetectable HIV RNA. HIV from this participant had no
mutations associated with drug resistance in HIV reverse transcriptase, protease, or integrase
assessed using an assay based on population sequencing. Results obtained using a research
assay based on NGS are shown in S2 Text; no integrase mutations were detected. Seven inci-
dent STIs were diagnosed in 6 participants during the primary analysis period: rectal chla-
mydia (2 cases), urinary chlamydia (1 case), urinary gonorrhea (1 case), dual rectal and
urinary gonorrhea (1 case), and early syphilis (1 case). All STIs except for syphilis were in
female participants.
CAB concentrations at all study visits, and the geometric means and their 90% prediction
intervals by sex at birth and cohort, are shown in Fig 5 for visits during the injection phase of
the study.
In Cohort 1 (800 mg every 12 weeks), geometric mean Cmax CAB concentrations were sig-
nificantly higher in male than in female participants following the first injection, and Cτ con-
centrations were significantly lower in male than in female participants following all 3
injections (Table 3). AUC0–τ was not significantly different between males and females. For
males in Cohort 1, 72%, 35%, and 32% of participants had Cτ concentrations that fell below 4×
PA-IC90 (0.166 μg/ml) at post-injection troughs 1, 2, and 3, respectively (Fig 6A, weeks 17, 29,
and 41). For females in Cohort 1, 24%, 5%, and 0% of participants’ Cτ concentrations fell
below 4× PA-IC90 at troughs 1, 2, and 3, respectively. Female participants’ Cτ CAB concentra-
tions were uniformly above the PA-IC90 after the third injection.
Fig 3. Study product discontinuation by cohort and arm (oral and injection phase). n = 199 (Cohort 1 CAB = 82;
Cohort 1 PBO = 28; Cohort 2 CAB = 69; Cohort 2 PBO = 20). AE, adverse event; CAB, cabotegravir; PBO, placebo.
https://doi.org/10.1371/journal.pmed.1002690.g003
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In Cohort 2 (600 mg every 8 weeks after an initial 4-week interval), injections occurred at
weeks 5, 9, 17, 25, and 33. With the first injection, male participants had significantly higher
Cmax, Cτ, and AUC0–τ CAB concentrations than female participants (Table 3). However, Cτ
CAB concentrations following the second, third, and fourth injections were significantly lower
in male participants than in female participants, while Cmax and AUC0–τ values did not signifi-
cantly differ between male and female participants. After the fifth injection, there were no sig-
nificant differences between Cmax, Cτ, and AUC0–τ values in male and female participants. In
Cohort 2, 79% or more of both male and female participants maintained Cτ CAB concentra-
tions above 4× PA-IC90 after all injections (Fig 6A).
When BMI was dichotomized at or above versus below median by sex at birth, Cohort 1
participants with lower BMI had numerically higher Cmax and AUC0–τ concentrations than
participants with higher BMI, which was statistically significant for the first injection only; Cτ
concentrations were not different for any injection. In Cohort 2, participants with lower BMI
Table 2. Grade 2 and higher AEs experienced by at least 5% of participants during the injection phase.
AE CAB LA (n = 134) PBO (n = 43) p-Value�
n (%) 95% CI n (%) 95% CI
AE� Grade 2 122 (91.0%) 85.0%, 94.8% 38 (88.4%) 75.5%, 94.9% 0.565
Serious adverse event 4 (3.0%) 1.2%, 7.4% 2 (4.7%) 1.3%, 15.5% 0.634
Creatinine renal clearance decreased† 63 (47.0%) 38.8%, 55.4% 20 (46.5%) 32.5%, 61.1% 1.000
Injection site reaction‡ 51 (38.1%) 30.3%, 46.5% 1 (2.3%) 0.4%, 12.1% <0.001
Musculoskeletal discomfort 34 (25.4%) 18.8%, 33.4% 6 (14.0%) 6.6%, 27.3% 0.145
Upper respiratory infection 31 (23.1%) 16.8%, 31.0% 10 (23.3%) 13.0%, 37.7% 1.000
Headache 22 (16.4%) 11.7%, 24.4% 4 (9.3%) 3.7%, 21.6% 0.326
Hypoglycemia 15 (11.2%) 6.9%, 17.6% 3 (7.0%) 2.4%, 18.6% 0.568
Influenza 14 (10.4%) 6.3%, 16.8% 3 (7.0%) 2.4%, 18.6% 0.766
Blood creatinine increased 13 (9.7%) 5.8%, 15.9% 3 (7.0%) 2.4%, 18.6% 0.764
Nasopharyngitis 14 (10.4%) 6.3%, 16.8% 2 (4.7%) 1.3%, 15.5% 0.364
Lipase increased 10 (7.5%) 4.1%, 13.2% 4 (9.3%) 3.7%, 21.6% 0.747
Conjunctivitis 11 (8.2%) 4.6%, 14.1% 1 (2.3%) 0.4%, 12.1% 0.298
Gastroenteritis 10 (7.5%) 4.1%, 13.2% 2 (4.7%) 1.3%, 15.5% 0.733
Urinary tract infection 11 (8.2%) 4.6%, 14.1% 1 (2.3%) 0.4%, 12.1% 0.298
Blood creatine phosphokinase increased 6 (4.5%) 2.1%, 9.4% 5 (12%) 5.1%, 24.5% 0.139
Rash 9 (6.7%) 4.1%, 13.2% 1 (2.3%) 0.4%, 12.1% 0.455
Dermatitis 8 (6.0%) 3.1%, 11.3% 2 (4.7%) 1.3%, 15.5% 1.000
Weight decreased 6 (4.5%) 2.1%, 9.4% 3 (7.0%) 2.4%, 18.6% 0.455
Genital candidiasis 7 (5.2%) 2.6%, 10.4% 1 (2.3%) 0.4%, 12.1% 0.682
Sinusitis 7 (5.2%) 2.6%, 10.4% 1 (2.3%) 0.4%, 12.1% 0.682
Depression 0 (0.0%) 0.0%, 2.8% 3 (7.0%) 2.4%, 18.6% 0.014
�p-Value for comparing the cabotegravir and PBO arms.
†Grade 2 AEs for creatinine clearance are determined by a result of <90 to 60 ml/min or a 10% to <30% decrease from baseline. Grade 3 AEs for creatinine clearance
are determined by a result of <60 to 30 ml/min or a 30% to <50% decrease from baseline. Of these participants, 42 (51%) had a decrease from baseline but maintained a
creatinine clearance�90 ml/min during the entire injection phase; 26 (31%) experienced a treatment-emergent decline in creatinine clearance to <90 ml/min.
Creatinine clearance returned to >90 ml/min during the injection phase for 20 (80%) of the 26 participants without interruption of study products. Fourteen
participants began the study with a Grade 2 creatinine clearance (<90 mm/min), which improved to >90 ml/min on study products, and then returned to <90 ml/min
creatinine clearance. One participant in the PBO arm experienced a transient decline in creatinine clearance from 70 ml/min to 57 ml/min.
‡Injection site pain in 47/52 (90%).
CAB LA, long-acting cabotegravir; PBO, placebo.
https://doi.org/10.1371/journal.pmed.1002690.t002
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also had higher Cmax and AUC0–τ concentrations with injections 1, 3 and 4; Cτ was also higher
in those with lower BMI after injection 1 (Table 4; Fig 6B). The distribution of Cτ relative to
PA-IC90 by BMI stratified by sex at birth is presented in S2 Fig. Results were similar when BMI
was dichotomized using a cutoff of 25 or 30 kg/m2; a nonlinear inverse relationship appears to
exist between BMI and pharmacokinetic parameters. This relationship is being explored fur-
ther in ongoing analyses.
Discussion
In HPTN 077, we administered 800 mg of CAB LA every 12 weeks (Cohort 1) or 600 mg of
CAB LA every 8 weeks (after an initial 4-week injection interval; Cohort 2) or PBO to HIV-
uninfected males and females in diverse geographic locations. This study builds on safety and
pharmacokinetic findings of a previous phase 2a study of CAB LA in men in the US, using the
800 mg every 12 weeks dose only. We found that both doses/intervals were well tolerated. ISRs
were very common, but infrequently led to injection discontinuation—at least with short-term
injection sequences over 36 weeks. No other safety concerns were identified. Pharmacokinetics
show that the 600 mg every 8 weeks dose used in Cohort 2 consistently met prespecified phar-
macokinetic targets based on macaque models using a rectal SHIV challenge.
Long-acting antiretroviral drugs for HIV treatment and prevention are of tremendous
interest, since they have the potential to minimize or eliminate some of the barriers associated
Fig 4. Proportion of participants reporting an injection site reaction resulting from each injection visit. (A) Proportion of Cohort 1 participants
reporting any injection site reaction. (B) Proportion of Cohort 2 participants reporting any injection site reaction. AE, adverse event; CAB LA, long-
acting cabotegravir; PBO, placebo.
https://doi.org/10.1371/journal.pmed.1002690.g004
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Fig 5. CAB concentrations by sex at birth and cohort. (A) Cohort 1 plasma CAB concentrations by sex at birth. (B) Cohort 2 plasma CAB
concentrations by sex at birth. Shaded areas represent the 90% prediction interval for the model. Time points indicated in red denote visits at
which injections were administered. Time 0 values represent plasma levels 1 week after last oral CAB dosing. PA-IC90 is the protein-adjusted
concentration at which 90% inhibition of viral replication is achieved. CAB, cabotegravir.
https://doi.org/10.1371/journal.pmed.1002690.g005
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with adherence to daily oral-tablet-based regimens. If proven safe and effective, the ability to
use long-acting injectable drugs discretely and without daily dosing has the potential to signifi-
cantly increase the proportion of at-risk individuals protected by antiretroviral-based preven-
tion strategies. HPTN 077 characterized the safety, tolerability, and pharmacokinetics of CAB
LA in males and females from regions disproportionally affected by the HIV epidemic. Impor-
tantly, we had the opportunity to test a 600 mg dose every 8 weeks, to study CAB LA in
women, and to study CAB LA in people in sub-Saharan Africa and Brazil. CAB LA is currently
in clinical development for both HIV treatment (in combination with long-acting rilpivirine
for maintenance of virologic suppression) and HIV prevention (as a single agent). In HPTN
077, we defined the pharmacokinetic parameters of CAB LA in both males and females at 8-
and 12-week dosing intervals while demonstrating the tolerability and safety of this agent in a
low-risk, HIV-uninfected population.
In the current study, CAB LA was generally well tolerated, with limited laboratory abnor-
malities. The only statistically significant difference in AEs between CAB and PBO was for
injection site pain. Although ISRs were common in participants receiving active CAB (approx-
imately 90% of participants in both cohorts), only 1 participant discontinued injections
because of an ISR. Two participants (1 in each cohort) who experienced severe (Grade 3) ISRs
with their first injection did not discontinue injections; both participants completed the full
series of injections. Although not reaching statistical significance, there appeared to be a
numerical decrease in reports of ISRs with repeated injections in both dosing cohorts. While
the difference in rates of ISRs between CAB LA and PBO recipients is striking, the majority of
Table 3. Geometric means of pharmacokinetic parameters (Cmax, Cτ, and AUC0–τ) by sex at birth.
Injection Parameter Cohort 1 Cohort 2
Female Male p-Value Female Male p-Value
1 n 49 25 39 20
Cmax (μg/ml) 1.89 2.67 0.019 1.58 2.51 0.003
Cτ (μg/ml) 0.95 0.49 <0.001 1.33 1.79 0.052
AUC0–τ (d
�μg/ml) 108.86 118.06 0.470 32.16 51.15 0.001
2 n 39 23 39 20
Cmax (μg/ml) 2.29 2.57 0.451 2.96 3.90 0.074
Cτ (μg/ml) 1.35 0.78 <0.001 1.82 1.29 0.024
AUC0–τ (d
�μg/ml) 152.86 133.24 0.254 125.05 146.59 0.264
3 n 35 22 37 20
Cmax (μg/ml) 3.01 3.39 0.461 3.46 2.96 0.325
Cτ (μg/ml) 1.65 0.82 <0.001 2.04 1.11 <0.001
AUC0–τ (d
�μg/ml) 208.19 184.51 0.332 156.29 124.76 0.117
4 n 36 19
Cmax (μg/ml) 3.33 2.96 0.460
Cτ (μg/ml) 2.06 1.46 0.032
AUC0–τ (d
�μg/ml) 149.04 121.57 0.166
5 n 32 18
Cmax (μg/ml) 3.66 3.82 0.800
Cτ (μg/ml) 2.03 1.68 0.259
AUC0–τ (d
�μg/ml) 167.83 163.04 0.849
Includes plasma cabotegravir concentrations obtained from samples collected within defined post-injection sampling windows.
AUC0–τ, area under the plasma concentration–time curve over the dosing interval; Cmax, maximum plasma concentration; Cτ, trough concentration at the end of the
dosing interval.
https://doi.org/10.1371/journal.pmed.1002690.t003
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Fig 6. Distribution of Cτ CAB concentrations relative to PA-IC90 by cohort and sex at birth and cohort and BMI (�median versus<median). (A)
Distribution of Cτ CAB concentrations by cohort and sex at birth. (B) Distribution of Cτ CAB concentrations by cohort and BMI. PA-IC90 is the protein-
adjusted concentration at which 90% inhibition of viral replication is achieved. BMI, body mass index; IM, intramuscular; Inj, injection; Q12W, every 12
weeks; Q8W, every 8 weeks.
https://doi.org/10.1371/journal.pmed.1002690.g006
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these reactions were mild or moderate and not treatment-limiting. Injection site tolerability
will be important to monitor carefully in phase 3 studies and, if CAB LA is shown to be safe
and effective for HIV prevention, in future open-label demonstration activities and research.
While it is notable that 20% of all Cohort 1 participants and 8% of all Cohort 2 participants
who began the injection phase did not complete the relatively short follow-up (Fig 2), the
majority of the discontinuations were due to rigorous mandated clinical and laboratory stop-
ping rules operationalized at regulatory behest, in order to be cautious with an investigational
long-acting, novel chemical entity under evaluation in low-risk, HIV-uninfected individuals.
One HIV infection occurred, 48 weeks after the third and final injection of 800 mg of CAB
LA. In this participant, CAB concentrations were below the limit of quantitation both at the
seroconversion visit and at the visit 12 weeks prior to seroconversion, when HIV tests indi-
cated that the participant was not HIV infected. This suggests that the exposure and HIV infec-
tion occurred in the setting of undetectable CAB concentrations. HIV resistance testing using
both population sequencing and NGS did not demonstrate the selection of integrase-associ-
ated mutations. The participant’s CAB concentrations during the injection period were consis-
tent with those of other participants in the Cohort 1 study population.
HPTN 077 was designed to supplement data from the previous phase 2a study of CAB LA
in US-based males [21] by providing multi-dose pharmacokinetic data for CAB LA in females.
During the conduct of HPTN 077 Cohort 1, it became clear from the earlier study that males
who received 800 mg every 12 weeks did not consistently achieve the PA-IC90 goals. Cohort 2
was therefore enrolled to provide data on the 600 mg every 8 weeks dose in both males and
Table 4. Geometric means of pharmacokinetic parameters (Cmax, Cτ, and AUC0–τ) by BMI (�median versus<median).
Injection Parameter Cohort 1 Cohort 2
�Median BMI� <Median BMI� p-Value �Median BMI� <Median BMI� p-Value
1 n 41 33 26 33
Cmax (μg/ml) 1.82 2.56 0.014 1.35 2.37 <0.001
Cτ (μg/ml) 0.73 0.81 0.454 1.12 1.82 0.001
AUC0–τ (d
�μg/ml) 99.09 130.12 0.010 27.47 48.24 <0.001
2 n 36 26 26 33
Cmax (μg/ml) 2.14 2.78 0.086 2.82 3.63 0.075
Cτ (μg/ml) 1.10 1.09 0.946 1.40 1.82 0.085
AUC0–τ (d
�μg/ml) 132.21 165.50 0.051 111.83 150.36 0.025
3 n 33 24 24 33
Cmax (μg/ml) 2.93 3.48 0.272 2.57 3.90 0.005
Cτ (μg/ml) 1.17 1.39 0.289 1.53 1.74 0.394
AUC0–τ (d
�μg/ml) 181.07 225.81 0.065 113.68 171.86 0.002
4 n 24 31
Cmax (μg/ml) 2.69 3.65 0.040
Cτ (μg/ml) 1.85 1.81 0.887
AUC0–τ (d
�μg/ml) 123.14 152.50 0.116
5 n 24 26
Cmax (μg/ml) 3.27 4.18 0.112
Cτ (μg/ml) 1.92 1.87 0.881
AUC0–τ (d
�μg/ml) 153.49 178.63 0.284
Includes plasma cabotegravir concentrations obtained from samples collected within defined post-injection sampling windows.
�Median BMI is 27.2 kg/m2 for females and 25.0 kg/m2 for males. AUC0–τ, area under the plasma concentration–time curve over the dosing interval; BMI, body mass
index; Cmax, maximum plasma concentration; Cτ, trough concentration at the end of the dosing interval.
https://doi.org/10.1371/journal.pmed.1002690.t004
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females. Follow-up of participants in Cohorts 1 and 2 was also extended to better characterize
CAB LA tail-phase pharmacokinetics.
HPTN 077 provides confirmatory data that males who receive CAB LA at a dose of 800 mg
every 12 weeks do not consistently achieve target trough concentrations. Females who received
the 800 mg quarterly dose fared better, only failing to meet pharmacokinetic targets at the first
trough time point (79% of trough concentrations were greater than 4× PA-IC90). In contrast,
all participants dosed with 600 mg every 8 weeks met the targets of 80% and 95% of partici-
pants with trough concentrations above 4× and 1× PA-IC90, respectively. Participants with
lower BMI were found to generally exhibit higher pharmacokinetic peak concentrations after
injection, as well as increased AUC concentrations. These BMI-related higher pharmacoki-
netic peaks were similar to findings in the previous male-only phase 2a study of CAB LA [21],
but here were noted to be recapitulated for female participants. The mechanism and signifi-
cance of these differences with respect to preventive efficacy will be evaluated in phase 3 clini-
cal trials. It is possible that local injection site fat content and distribution may be contributing
to altered pharmacokinetics, which will have important implications for other large-muscle
injection options. Currently, CAB LA is only recommended for injection in the buttock region
(gluteus medius or gluteus maximus). Should regulatory approvals be successful, there is inter-
est in expanding injection site options, including the potential for anterior thigh self-injection;
however, the suggestion of muscle fat-content related pharmacokinetic differences will obli-
gate additional clinical evaluation before the use of alternative sites can be sanctioned. It is
reassuring that macaque studies of SHIV challenge breakthrough infections did not result in
resistant virus.
In an earlier phase 2a study in US males, CAB levels were still detectable at 52 weeks post-
injection in 17% of participants [21]. HPTN 077 tail-phase pharmacokinetic data are not yet
available. Pharmacokinetic data from the long-term follow-up of study participants were col-
lected for up to 76 weeks after final injection. The description of these tail-phase kinetics in
males and females (for whom the terminal decay rate is anticipated to be 50% slower than for
males) will be important to the discussion of the risk for seroconversion and subsequent selec-
tion of CAB-resistant virus. This is of particular concern should HIV seroconversion occur
during the period of CAB persistence below some critical, as yet to be determined threshold.
This study has several limitations. The sample size in each cohort may have limited our abil-
ity to detect rare AEs and to find smaller safety differences between cohorts and between CAB
and PBO study arms. Assessment of ISRs between safety visits was limited to self-report and
may have been influenced by recall bias when participants presented to the clinic. Sexual risk
and adherence to oral study product were assessed by self-report and pill count, which are sub-
ject to social desirability bias and manipulation, respectively. Stringent stopping criteria in
both the oral and injection phases of the study likely mandated more discontinuations than
would be undertaken in either a phase 3 study or clinical practice. The limited number of
transgender participants enrolled precludes robust subset analyses in this population; appro-
priately powered studies for transgender individuals are needed. Additionally, this low-risk
population is not the intended target population for PrEP; some findings, such as tolerability
and acceptability, may differ in meaningful ways from findings in those who are at higher risk
of HIV infection and will be examined in phase 3 studies. Finally, the safety of CAB in women
of childbearing potential will be of critical importance when considering the scalability of CAB
LA PrEP for global use, even if proven effective in clinical studies. An ongoing phase 3 clinical
trial enrolling women of childbearing potential will further define its safety profile in this
population.
Other long-acting or extended release agents under investigation for HIV prevention
include a nanosuspension of rilpivirine [25], broadly neutralizing monoclonal antibodies [26],
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subdermal implants that would elute agents from a removable or degradable depot (similar to
implantable contraception) [27], and vaginal rings impregnated with dapivirine [28,29].
HPTN 077 demonstrated the safety and favorable pharmacokinetics for CAB LA at a dose
of 600 mg intramuscularly administered every 8 weeks after an initial 4-week dosing interval
in a global population of males and females. These results support the CAB LA dose selected
for the current designs of the phase 3 studies HPTN 083 and HPTN 084 (NCT02720094 and
NCT03164564 [https://www.hptn.org/research/studies]). These fully powered studies in high-
risk populations are directly comparing the efficacy and safety of long-acting injectable CAB
to standard of care daily oral TDF/emtricitabine in North and South America, Africa, and
Asia.
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